Fisher Scientific International Inc

Fisher Scientific International — Robert W. Baird 2004 Growth Stock Conference

25 slides from Fisher Scientific International's conference presentation, May 4, 2004

  1. Slide 1: The World Leader in Serving Science

    Slide 1: The World Leader in Serving Science

    The World Leader in Serving Science Robert W. Baird 2004 Growth Stock Conference May 4, 2004

  2. Slide 2: Safe Harbor and Regulation G Statement

    Slide 2: Safe Harbor and Regulation G Statement

    This presentation contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on Fisher's and Apogent's current expectations and beliefs and are subject to a number of risks, uncertainties and a

  3. Slide 3: Fisher at a Glance

    Slide 3: Fisher at a Glance

    Fisher at a Glance - Founded in 1902 Proprietary 60% Distributed 40% 80% Consumable * Includes effect of the Apogent transaction. 350,000 customers Global scientific research $20 U.S. clinical laboratory $10 2004E Sales $4.6B EPS $2.81 Growing Markets ($ Bils) Favorable market dynamics Extensive Lif

  4. Slide 4: Diverse Customer Base

    Slide 4: Diverse Customer Base

    7 Scientific Research 75% Clinical Lab 25% No Customer > 2.5% of Sales Diverse Customer Base Pharma 0.23 Hospitals 0.17 Reference Labs / Other 0.08 Other 0.33 Medical Research 0.08 Colleges and Universities 0.11

  5. Slide 5: Market Dynamics Are Favorable

    Slide 5: Market Dynamics Are Favorable

    Pharma 0.23 Hospitals 0.25 Other 0.33 Medical Research 0.08 Colleges and Universities 0.11 R&D spending steadily increasing Market Dynamics Are Favorable Customer Base 9 Pharma/Biotech 23% Colleges & Universities 11% Medical Research 8% Other Scientific Research 33%

  6. Slide 6: Market Dynamics Are Favorable

    Slide 6: Market Dynamics Are Favorable

    Pressure on drug development costs R&D spending steadily increasing Market Dynamics Are Favorable Customer Base Pharma 0.23 Hospitals 0.25 Other 0.33 Medical Research 0.08 Colleges and Universities 0.11 Pharma/Biotech 23% 11

  7. Slide 7: Market Dynamics Are Favorable

    Slide 7: Market Dynamics Are Favorable

    Pressure on drug development costs Aging population R&D spending steadily increasing Market Dynamics Are Favorable Customer Base Pharma 0.23 Hospitals 0.25 Other 0.33 Medical Research 0.08 Colleges and Universities 0.11 Pharma/Biotech 23% Colleges & Universities 11% Medical Research 8% Hospitals & R

  8. Slide 8: Market Dynamics Are Favorable

    Slide 8: Market Dynamics Are Favorable

    Pressure on drug development costs Aging population R&D spending steadily increasing Growth in homeland security spending Market Dynamics Are Favorable Customer Base 15 Pharma 0.23 Hospitals 0.25 Other 0.33 Medical Research 0.08 Colleges and Universities 0.11 Hospitals & Reference Labs / Other 25% O

  9. Slide 9: Company Capabilities

    Slide 9: Company Capabilities

    The Fisher brand Global logistics Industry-leading sales force Company Capabilities

  10. Slide 10: The Fisher Brand

    Slide 10: The Fisher Brand

    100 years of serving science Broad proprietary product and service portfolio Global brand recognition Company Capabilities The Fisher Brand

  11. Slide 11: Global Logistics Capabilities

    Slide 11: Global Logistics Capabilities

    Global Logistics Capabilities Company Capabilities 30,000 shipments daily 39 distribution facilities E-commerce systems

  12. Slide 12: Industry-Leading Sales Force

    Slide 12: Industry-Leading Sales Force

    1,500 sales reps 1,200 customer service reps Industry-Leading Sales Force Company Capabilities Supply chain solutions 375* life science, chemical and technical specialists End-user sales and support *Will increase to approximately 800 specialists upon completion of the Apogent transaction.

  13. Slide 13: Key Strategies

    Slide 13: Key Strategies

    Key Strategies Increase proprietary product and service offering Capitalize on high growth life science market Increase earnings and cash flow growth 25

  14. Slide 14: Apogent Transaction Benefits

    Slide 14: Apogent Transaction Benefits

    Apogent Transaction Benefits Enhances portfolio of proprietary products and services Increases Fisher's life science footprint to $1.1 billion Strengthens Fisher's healthcare business Provides significant cost savings opportunities Increases cash flow generation Apogent - A perfect fit 27

  15. Slide 15: Apogent Merger - Improved Product Mix

    Slide 15: Apogent Merger - Improved Product Mix

    Apogent Merger - Improved Product Mix Life Science Products 0.33 Scientific Research Products 0.18 Other Equipment 0.17 Clinical Lab Products 0.32 Based on pro forma 2004 sales Life Science Products 0.18 Scientific Research Products 0.55 Lab Workstations 0.09 Clinical Lab Products 0.23 Pro forma 200

  16. Slide 16: Apogent Merger - Synergies

    Slide 16: Apogent Merger - Synergies

    Provides up to $100 million of cost savings Rationalize Fisher's and Apogent's manufacturing operations Consolidate administrative functions and public company expense Reduce logistics expense and leverage combined purchasing power Apogent Merger - Synergies 31

  17. Slide 17: Financial Highlights

    Slide 17: Financial Highlights

    Financial Highlights

  18. Slide 18: First Quarter Results

    Slide 18: First Quarter Results

    * Excludes foreign exchange. Organic growth was 8% in Q1 2004 versus 4% in Q1 2003. Excludes restructuring and non-recurring expenses. 2003 2004* East 833.4 983.5 ($ in Millions, Except Earnings Per Share) 2003 2004 East 0.48 0.6 2003 2004 East 55.8 66 Sales EPS Operating Cash Flow Operating Income

  19. Slide 19: Sales Growth

    Slide 19: Sales Growth

    Sales Growth ($ in Billions) 2000 2001 2002 2003 2004F* 2005F* *Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Excludes the impact of foreign exchange. CAGR: 16%

  20. Slide 20: Earnings Per Share Growth and Operating Margins

    Slide 20: Earnings Per Share Growth and Operating Margins

    Earnings Per Share Growth ($ in Millions) 2000 2001 2002 2003 2004F* 2005F* Excludes goodwill amortization, restructuring and nonrecurring expenses. * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. CAGR: 24% Operating Margins 6.8% 7.3% 7.5% 7.8% 1

  21. Slide 21: Strong Operating Cash Flow

    Slide 21: Strong Operating Cash Flow

    Strong Operating Cash Flow 2000 2001 2002 2003 2004F 2005F ($ in millions) Free cash flow is cash from operations less capital expenditures. * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Memo: Free Cash Flow $78 $119 $115 $138 $215 $395 * *

  22. Slide 22: Investment Highlights

    Slide 22: Investment Highlights

    Investment Highlights Strong earnings and cash flow growth Favorable market dynamics Significant margin enhancement opportunities Strong management team

  23. Slide 23: Questions and Answers

    Slide 23: Questions and Answers

    Questions and Answers

  24. Slide 24: Supplementary Financial Information

    Slide 24: Supplementary Financial Information

    (in millions, except per share amounts) Supplementary Financial Information

  25. Slide 25: Additional Information about the Merger

    Slide 25: Additional Information about the Merger

    In connection with the proposed merger, Fisher Scientific and Apogent Technologies will file relevant materials with the SEC, including one or more registration statement(s) that contain a prospectus and a joint proxy statement, including one that was filed on April 16, 2004. Investors and security

Source: SEC EDGAR · 425 filed May 4, 2004

More decks from Fisher Scientific International Inc